Vistagen Taps Dr. Angel Angelov as Chief Medical Officer

Vistagen, a late clinical-stage biopharmaceutical company, has appointed Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO).

“We are pleased to welcome Dr. Angelov to the Vistagen team,” said Shawn Singh, President and CEO of Vistagen. “His two decades of leadership across clinical development and medical affairs, including roles at Karuna, Neurocrine, Novartis, and Teva, will be instrumental as we work to improve suboptimal standards of care in our targeted therapeutic areas.”

Experience

Angelov most recently served as CMO at Theranica, a neuromodulation therapeutics company. Previously, he served as Managing Director at ANG Holding, as Vice President, Head of Medical Affairs at Karuna Therapeutics (now a wholly owned subsidiary of Bristol Myers Squibb), and as Vice President, Clinical Leader for the VMAT-2 Franchise and Head of Medical Affairs at Neurocrine Biosciences.

He has also held clinical development and medical affairs positions at CollaGenex, Indivior, Novartis, NuPathe, and Teva, as well as faculty positions at Thomas Jefferson University and Temple University.

Angelov earned his M.D. from Sofia Medical University and completed his residency and fellowship training at Thomas Jefferson University. He also earned an MBA from the Wharton School at the University of Pennsylvania. Angelov is Board Certified in Psychiatry, is a diplomate of the American Board of Psychiatry and Neurology and holds an active Pennsylvania medical license.

“I am honored and excited to join Vistagen, a team so deeply committed to addressing critical areas of unmet need across multiple therapeutic areas such as neuropsychiatry and women’s health,” Angelov said. “Vistagen’s pioneering work with neurocircuitry-focused pherines represents a compelling opportunity to reshape how we approach patient care. I look forward to contributing to Vistagen’s mission to deliver transformative treatments and improve lives, alongside a team that shares my commitment to patient care and scientific innovation.”

Related News

In December 2025, Vistagen appointed Nick Tressler as Chief Financial Officer (CFO).